PTO/SB/17 (01-06) Approved for use through 7/31/2006. OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number. Complete if Known ursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818). 10/564,397 Application Number FEE TRANSMIT Filing Date Jan. 3, 2006 For FY 2006 **Evans TARACHA** First Named Inventor **Examiner Name** Unassigned Applicant claims small entity status. See 37 CFR 1.27 Unassigned Art Unit TOTAL AMOUNT OF PAYMENT 41860-227341 0.00 (\$) Attorney Docket No. METHOD OF PAYMENT (check all that apply) Check Credit Card Money Order None Other (please identify): X Deposit Account Deposit Account Number: 22-0261 Deposit Account Name: Venable LLP For the above-identified deposit account, the Director is hereby authorized to: (check all that apply) Charge fee(s) indicated below Charge fee(s) indicated below, except for the filing fee Charge any additional fee(s) or underpayment of Credit any overpayments fee(s) under 37 CFR 1.16 and 1.17 FEE CALCULATION (All the fees below are due upon filing or may be subject to a surcharge.) 1. BASIC FILING, SEARCH, AND EXAMINATION FEES **FILING FEES SEARCH FEES EXAMINATION FEES Small Entity Small Entity** Small Entity **Application Type** Fee (\$) Fee (\$) Fee (\$) Fee (\$) Fee (\$) Fee (\$) Fees Paid (\$) Utility 300 500 150 250 200 100 Design 200 100 100 50 130 65 Plant 200 100 300 150 160 80 300 150 500 600 Reissue 250 300 200 100 Provisional 0 0 0 2. EXCESS CLAIM FEES **Small Entity** Fee (\$) Fee (\$) Fee Description Each claim over 20 (including Reissues) 50 25 Each independent claim over 3 (including Reissues) 200 100 Multiple dependent claims 360 180 **Total Claims Extra Claims** Fee Paid (\$) **Multiple Dependent Claims** Fee Paid (\$) Fee (\$) HP = highest numer of total claims paid for, if greater than 20. Indep. Claims **Extra Claims** Fee Paid (\$) HP = highest numer of independent claims paid for, if greater than 3. 3. APPLICATION SIZE FEE If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). Extra Sheets **Total Sheets** Number of each additional 50 or fraction thereof Fee Paid (\$) Fee (\$) - 100 = ____ (round up to a whole number) x 4. OTHER FEE(S) Fees Paid (\$) Non-English Specification, \$130 fee (no small entity discount) Other (e.g., late filing surcharge):

SUBMITTED BY	.)					
Signature	Namey Age	lml	Registration No. (Attorney/Agent)	44,014	Telephone	(202) 344-4000
Name (Print/Type)	Nancy J. Axelrod				Date	July 11, 2006

PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number 10/564,397 **TRANSMITTAL** Filing Date Jan. 3, 2006 First Named Inventor **FORM Evans TARACHA** Art Unit Unassigned (to be used for all correspondence after initial filing) **Examiner Name** Unassigned Attorney Docket Number

I otal Numbe	er of Pages in This Submiss	sion 24	•	41860-227341				
ENCLOSURES (Check all that apply)								
x Fee Transmittal Form		Drawing(s)		After Allowance Communication				
Fee Attached		Licensing-related Papers		Appeal Communication to Board of Appeals and Interferences				
Amendme	nt/Reply	Petition		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)				
After	r Final	Petition to Co Provisional A		Proprietary Information				
Affid	avits/declaration(s)		ney, Revocation respondence Address	Status Letter				
Extension	of Time Request	Terminal Disc	laimer	Other Enclosure(s) (please Identify below):				
Express A	bandonment Request	Request for Refund CD, Number of CD(s)		PTO/SB/08a/b				
X Information	n Disclosure Statement			International Search Reports (2)				
Certified C Document	opy of Priority (s)	Landscape Table on CD						
	lissing Parts/ e Application	Remarks						
	y to Missing Parts under FR 1.52 or 1.53							
	SIGNATU	JRE OF APPLICA	NT, ATTORNEY, OF	RAGENT				
Firm Name VENABLE LLP								
Signature	Signature Name Action							
Printed name								
Date July 11, 2006			Reg. No.	44,014				

JUL 11 2006



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Evans TARACHA et al.

Application No.: 10/564,397

Filed: Jan. 3, 2006

For: EAST COAST FEVER VACCINE BASED

ON CTL-SPECIFIC SCHIZANT ANTIGENS

Confirmation No.:

Art Unit: Unassigned

Examiner: Unassigned

Attorney Docket No. 41860-227341

Customer No.

26694
PATENT TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

This is an Information Disclosure Statement submitted under 37 C.F.R. § 1.97 within the time specified under 37 C.F.R. § 1.97(b).

Documents CA-CQ are cited in the International Search Report for International Application No. PCT/US2004/022605 (the PCT parent application of this application), and in the International Search Report for International Application No. PCT/US2004/030831 (the PCT parent for application S/N 10/573,033, attorney docket no. 41860-229250 (a related application)). A copy of the two International Search Reports is also enclosed.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore no Statement Under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In view of the above, no further translation or statement of relevance is required, and as all requirements of 37 C.F.R. § 1.97 and all official guide lines pertaining to Information

Disclosure Statements have been complied with, it is therefore respectfully requested that the

Evans TARACHA et al. App. No. 109/564,397

Examiner consider the documents and make them of record.

Please charge any necessary fee or credit any overpayment in connection with this Information Disclosure Statement to Deposit Account No. 22-0261.

Respectfully submitted,

Date: July 11, 2006

Nancy J. Axelrod

Registration No. 44,014

VENABLE

P.O. Box 34385

Washington, D.C. 20043-9998

Telephone: (202) 344-4000 Telefax: (202) 344-8300

Doc #742859

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known					
Application Number	10/564,397				
Filing Date	Jan. 3, 2006				
First Named Inventor	Evans TARACHA				
Art Unit	Unassigned				
Examiner Name	Unassigned				
Attorney Docket Number	41860-227341				

			U.S. PA	TENT DOCUMENTS	
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No.1	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
	AA	5,273,744	12/28/1993	Musoke et al.	
	AB				
	AC				

		FOREIG	ON PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ ⁶
	ВА					
	BB					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	CA	"EST628571 TpMugugaSh01 Theileria parva cDNA clone TPFAN22, mRNA sequence," 01/02/2003, DATABASE EMBL 'Online!, XP002318733.		
	СВ	"EST627619 TpMugugaSh01 Theileria parva cDNA clone TPFAF71, mRNA sequence," 01/02/2003, DATABASE EMBL 'Online!, XP002330785.		
	CC	"EST627620 TpMugugaSh01 Theileria parva cDNA clone TPFAF71, mRNA sequence," 01/02/2003, DATABASE EMBL 'Online!, XP002330786.		
	CD	"EST627151 TpMugugaSh01 Theileria parva cDNA clone TPFAC45, mRNA sequence," 01/02/2003, DATABASE EMBL 'Online!, XP002330787.		
	CE	"EST627152 TpMugugaSh01 Theileria parva cDNA clone TPFAC45, mRNA sequence," 01/02/2003, DATABASE EMBL 'Online!, XP002330788.		
	CF	"EST629769 TpMugugaSh01 Theileria parva cDNA clone TPFAU35, mRNA sequence," 01/02/2003, DATABASE EMBL 'Online!, XP002310756.		
	CG	"T.parva heat shock protein 90 (hsp90) mRNA, complete cds.," 02/21/1991, DATABASE EMBL 'Online!, XP002323332.		
	СН	"EST630891 TpMugugaSh01 Theileria parva cDNA clone TPFDB90, mRNA sequence," 01/02/2003, DATABASE EMBL 'Online!, XP002323333.		
CI "Translation initiation factor eIF-1A, putative," 01/03/2003, DATABASE Uniprot 'Online!, XP002323334.				
	CJ	"EST630890 TpMugugaSh01 Theileria parva cDNA clone TPFDB90, mRNA sequence," 01/02/2003, DATABASE EMBL 'Online!, XP002323335.		
	CK	"EST630359 TpMugugaSh01 Theileria parva cDNA clone TPFAY47, mRNA sequence,"		
Examiner Signature		Date Considered		

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	Substitute for form 1449A/B/PTO			Complete if Known		
				Application Number	10/564,397	
l IN	NFORMATION	1 DI	SCLOSURE	Filing Date	Jan. 3, 2006	
S	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Evans TARACHA	
				Art Unit	Unassigned	
	(Use as many sheets as necessary)			Examiner Name	Unassigned	
Sheet	2	of	2	Attorney Docket Number	41860-227341	

	01/02/2003, DATABASE EMBL 'Online!, XP002323336.
CL	"EST628661 TpMugugaSh01 Theileria parva cDNA clone TPFAM54, mRNA sequence," 01/02/2003, DATABASE EMBL 'Online!, XP002323337.
СМ	BALLINGALL, K. T. ET AL, "A highly sensitive, non-radioactive assay for T cell activation in cattle: applications in screening for antigens recognized by CD4<+> and CD8<+> T cells," J of Immunological Methods, May 2000, pp. 85-93, vol. 239, no. 1I-2, Elsevier Science Pub. BV, Amsterdam.
CN	GARDNER M. J. ETAL, "Genome Sequence of the Human Malaria Parasite Plasmodium Falciparum," Nature, 2002, pp. 498-511, vol. 419, Macmillan Journals Ltd., London.
СО	GERHARDS, JOACHIM ET AL., "Sequence And expression of a 90-kilodalton heat-shock protein family member of Theileria parva," Molecular and Biochemical Parasitology, 1994, pp. 235-246, vol. 68, no. 2.
СР	MCKEEVER, DECLAN J. ET AL., "Novel vaccines against Theileria parva: Prospects for sustainability," Int'l J for Parasitology, May 1998, pp. 693-706, Vol. 28, no. 5.
CQ	MORRISON W. IVAN ET AL., "Theileriosis: Progress towards vaccine development through understanding immune responses to the parasite," Veterinary Parasitology, 1995, pp. 177-187, vol. 57, no. 1-3.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	l

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.